Cardiovascular

Sanofi, Regeneron field  pre-launch cholesterol IQ poll

Sanofi, Regeneron field pre-launch cholesterol IQ poll

By

The drugmakers, who have an experimental cholesterol medication in the works, are asking consumers what they know about heart health.

Bayer launches respiratory awareness contest

Bayer launches respiratory awareness contest

By

Encouraging competitors to take an artistic approach to "Breathless Moments," the competition is a first for Bayer, which is already working on next year's effort.

Analyses support Pradaxa safety profile

Analyses support Pradaxa safety profile

By

Results of two post-market studies, conducted in part by Boehringer Ingelheim, corroborate the billion-dollar blood thinner's benefit/risk profile.

PCSK9s stalk Merck's Vytorin

PCSK9s stalk Merck's Vytorin

By

A head-to-head comparison between Sanofi and Regeneron's experimental PCSK9 shows alirocumab lowers LDL levels more effectively than Merck's Zetia, which is part of the just-acquitted Vytorin.

Study finds new benefits in highly promising heart drug

A pipeline drug from Novartis has the potential to alter the progression of heart disease and keep patients out of the hospital.

Merck's IMPROVE-IT trial hits big, supports wider Zetia use

Merck's IMPROVE-IT trial hits big, supports wider Zetia use

By

Patients taking Vytorin experienced a 6.4% reduced relative risk for cardiovascular events, the company said.

Five things for pharma marketers to know: Monday, November 17

Five things for pharma marketers to know: Monday, November 17

By

Actavis and Allergan have a $66-billion-dollar deal, Merck's Vytorin hits its endpoint, and Pfizer puts up $850 million for an experimental cancer drug.

Five things for pharma marketers to know: Thursday, November 13

Five things for pharma marketers to know: Thursday, November 13

By

Actavis and Allergan are close to a deal in the $60-billionish range; AstraZeneca is working on a Brilinta antidote; scientists find what amounts to a naturally occurring version of Merck's Zetia.

Coalition urges gender-specific heart research

Coalition urges gender-specific heart research

By

The industry-supported group WomenHeart launched a heart failure awareness campaign Wednesday, as well as a push for gender-specific research.

Pradaxa antidote enters Phase III

Testing has already started abroad, and Boehringer says this is the first clinical trial that tests an antidote among patients taking a new oral anticoagulant.

Five things for pharma marketers to know: Friday,  October 17

Five things for pharma marketers to know: Friday, October 17

By

Amgen sues Sanofi and Regeneron over PCSK9 patents; FDA panel wants Chantix black box to stay; Valeant-Allergan uproar rises in pitch; Pharmacyclics and Roche team up against CLL; and GSK's Ebola vax may "miss" the current crisis.

Analysts see potential in Novartis's serelaxin

Analysts see potential in Novartis's serelaxin

By

Two regulatory agencies have rejected the drug, but analysts indicate the pipeline acute heart failure treatment could have limited market success.

Five things for pharma marketers to know: Friday, October 3

Five things for pharma marketers to know: Friday, October 3

By

Salix-Cosmo tax-inversion deal quashed, chronic heart failure market set to expand, rising generic drug prices get lawmakers' attention, NICE gives leukemia drug a thumbs-down, FDA has a good rep

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.

Mylan buys branded and generic Arixtra

The $225-million deal will give Mylan one of two generics for the deep vein thrombosis drug.

Novartis may have game-changing drug

Novartis may have game-changing drug

By

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

By

Evolocumab holds the FDA's first filed biologics license application for the class.

GAO tallies cost-effective interventions

GAO tallies cost-effective interventions

By

Half-measures, like diabetes educational materials without a part B, fared poorly.

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

By

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

Study questions HDL medication benefit

A study indicates they may do little to reduce the risk of stroke or heart attack.

Merck stifles ezetimibe criticism

The head of evidence-based medicine at Milan's health authority Alberto Donzelli has pulled down criticism of Merck's cholesterol drug ezetimibe from his website, after the drugmaker sent two cease-and-desist letters.

Study links DPP-IV medication to heart failure, hospitalization

Editorial says risk is small, researchers say it could be clinically relevant.

Diovan competition is coming

Novartis no longer has a lock on the Diovan market: the FDA approved Ranbaxy's generic, which will be made in the US.

Triglycerides, not HDL, may be cardio bad guys

Gene mutations lead researchers to rethink ways to protect the heart.

Statins linked to less exercise, more diabetes

Two studies found two different facets of statin therapy—one found patients moved less a year after starting their regimens, and another that the drugs upped the diabetes risk for some.

Cigna expedites Crestor use

Cigna expedites Crestor use

By

The company signed a deal with AstraZeneca in which high-risk heart disease patients can bypass step therapy and go straight to the branded cholesterol fighter.

Boehringer settles Pradaxa suits

The company is settling around 4,000 cases for around $162,500 apiece.

BI's Pradaxa antidote progresses

The drugmaker is set to start patient testing.

FDA says no to Novartis heart drug

FDA says no to Novartis heart drug

By

Novartis says the FDA wants more serelaxin efficacy data.


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.

Email Newsletters